Skip to main content
. Author manuscript; available in PMC: 2014 Jul 14.
Published in final edited form as: Tumour Biol. 2014 Jan 8;35(3):2661–2667. doi: 10.1007/s13277-013-1350-6

Fig. 2.

Fig. 2

Western blotting analysis showing representative breast cancer sera recognizing p90/CIP2A recombinant protein. The monoclonal anti-p90/CIP2A antibody was used as positive control; lanes 1–5, five representative breast cancer sera that were positive in ELISA test and also have strong reactivity with p90/CIP2A recombinant protein in western blotting analysis; lanes 6 and 7, normal human sera were used as negative control